T Cell Engagers 2 / Antibody-Drug Conjugates 1

• 5582 · PDF Trispecific TCE with second signal boosts solid tumor response efficacy, durability and safety Yuanyuan Wang, Huijuan Lu, Hanmian Cai, Chun Liu, Liang Xiao, Peipei Hu, Chang Zhou, Yongting Huo, Di Lu
• 5584 · PDF TCX-101, a trispecific T-cell engager (TcE) co-targeting a tumor-associated carbohydrate (TACA) antigen and a tumor-associated protein antigen (TAA) for the treatment of solid tumors with enhanced preclinical activity Karla E. G. Soto, Francesco Muraca, Stephan Grunwald, Wiebke Winkler, Carolin Lange, Jean Engela, Peter Sondermann, Matthias Ocker
• 5585 · PDF ARK102, a novel tri-specific T cell engager targeting TROP2, HER2, and CD3 for treatment of solid tumors Kyeongsik Min, Deukjoo Ahn, Sangwoo Park, Jaejin Jeon, Heeyeon Kim, Yongwon Jung, Yong-Boo Kuk, Jeongmin An, Taehwan Jeong, Seungwon Lee
• 5586 · PDF A next-generation CD8-selective tri-specific T cell engager targeting CDH17 with enhanced efficacy and reduced toxicity Jian Guo, Jiaojiao Ding, Tian Wang, Hanmian Cai, Liang Xiao, Peipei Hu, Chang Zhou, Yongting Huo, Di Lu
• 5587 · PDF VTS208: A first-in-class CD3/CLDN18.2/CDH17 Tri-specific T cell engager (TCE) for the treatment of gastrointestinal (GI) cancer Wei (Vivian) Wang, Xuekun Zhang, Man Xu, Yingchun Wang, Mei Yuan, Yanwei Wang, Liping Chen, Yanling Gong, Jing Li
• 5588 · PDF A next-generation tri-specific T cell engager targeting CDH17 with 4-1BB co-stimulation for the treatment of gastrointestinal cancers Shan Gao, Xiaoli Zhang, Yuanyuan Yang, Zhijian Cai, Feifei Cui, Liu Yang, Lei Fang
• 5589 · PDF A biparatopic DLL3-targeting trispecific T-cell engager delivered by mRNA-LNP drives potent anti-tumor activity in vitro and in vivo Xue Qiao, Qiang Zhang, Lushuai Jin, Yao Lv, Shaoli Liu, Xiaoju Zhang, Xiaoyun Ma, Hongya Han, Wei Xu
• 5590 · PDF BCG024: A novel DLL3×CD3×4-1BB trispecific T cell engager enhances T cell persistence and functionality in preclinical models Guan Wang, Baihong Liu, Liu Yang, Xue Li, Shuangshi Liu, Yu Qi, Jinhua Zhao, Yang Chen, Frank An, Yi Yang
• 5591 · PDF Development of a novel anti-CD19 x BCMA dual targeted T cell engager for the treatment of autoimmune diseases and B cell malignancies Lin Huan, Hao Ran, Shiyi Wang, Xiaoping Zhang, Bing Yang, Yang He, Dandan Liu, Chenpeng Su, Chuan Chen, Xiaoqian Chen, Kezhen Ye, Liang Tian, Jian Peng, Zhenping Zhu
• 5592 · PDF QL535: A novel CD2-costimulating PSMA-targeted T-cell engager with dose-responsive efficacy in PDX models and a favorable GLP toxicology profile in NHP Xiao Liu
• 5593 · PDF A CD19/BCMA dual-targeting VHH format T-cell engager with novel CD3 binder for enhanced potency and safety profile Fan Wu, Yongfeng Li, Liang Xiao, Chang Zhou, Peipei Hu, Jiya Shi, Tingchu Wu, Yue Huang, Mengying Liang, Chun Liu, Yuanyuan Wang, Yongting Huo, Di Lu
• 5594 · PDF Pharmacological integration of CD3 and CD2 signaling triggers formation of a CD2 corolla that boosts T cell activation Sergio Trombetta, Shengpan Zhang, Tanmay Mitra, Salvatore Valvo, Colleen Brown, Oksana Segreeva, Stella Martomo, Martin Preyer, Jay Fine, Jeremy Myers, Michael Dustin
• 5595 · PDF Development of EDP001, a tetravalent T Cell engager targeting CD19 and BCMA for B Cell lymphoma Qinglin Du, Zongjun Xia, Pan Du, Xing Wang, Xiaoman Wang, Feng Wang, Xueyan Yang, Yi Wu, Shuhua Han
• 5597 · PDF Plinabulin boosts antitumor efficacy of topoisomerase inhibitor-based antibody-drug conjugates without or with immune checkpoint inhibitor Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang, James Tonra, Lan Huang
• 5598 · PDF Exploiting electron transport chain dynamics to sensitize OXPHOS-dependent cancers to immunotherapy Haojie Dong, Guoyun Kao, Umesh P. Yadav, Lei Zhang, Arshad J. Ansari, Srinivasarao Singireddi, Bei Jia, Jianai Sun, Guohua Wu, Yini Wang, Xin He, Lei Zhang, Zheng Li, Ruiheng Wang, Wei Chen, Meng Liu, Shuaishuai Ge, Yang Li, Whitaker Cohn, Amandeep Salhotra, David B. Sykes, Jie Jin, Jianjun Chen, Guido Marcucci, Shoubao Ma, Hong Zheng, Yong Zhang, Ling Li
• 5599 · PDF ATG-125, a novel B7H3 × PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion and direct tumor killing Jishun Chen, Suya Bai, Yu Bai, Huiling Liu, Zaoshun Hu, Jay Mei, Peng Chen, Bing Hou
• 5601 · PDF LBL-061: A novel EGFR×PD-L1 targeted drug conjugate for the treatment of multiple solid tumors Yurong Qin, Yang Ye, Yujia Dang, Juan Tang, Peng Zhang, Yan Zhu, Shuijun Hu, Mi Ye, Xiaoxiao Liu, Xu Bao, Huan Lin, Wanting Wang, Guojin Wu, Jianming Sun, Hui Yuwen, Yuanzhi Lv, Jing Guan, Min Chen, Yue Zhao, Jordan Zhu, Charles Cai, Xiao Huang, Xiaoqiang Kang, Hong Ling
• 5602 · PDF Novel ATR inhibitor payloads for antibody-drug conjugates targeting PD-L1 Anne Roulston, Martin Duplessis, Francois Denis, Hugo Poirier, Shou Yun Yin, Sara Fournier, Roselyn Kryczka, Jessica Desjardins, Nancy Laterreur, Abira Rajah, Alexanne Bonneau-Fortin, Bingcan Liu, Alejandro Alvarez-Quilon, Philipe Mochirian, Ismael Samudio
• 5603 · PDF Targeting B7-H3 in the small cell lung carcinoma (SCLC) tumor-immune microenvironment (TIME) Marco Campisi, Carla Stornante, Ian D. Dryg, Harrison Olszewski, Alan E. Bers, Ian Gillanders, Kathleen Pfaff, Robert Gentleman, Scott Rodig, Navin R. Mahadevan, David A. Barbie
• 5604 · PDF TAK-188, an antibody-drug conjugate with a novel amanitin payload, disrupts immune suppression and leads to potent anti-tumor immunity through selective depletion of CCR8 + intratumoral regulatory T-cells Cierra N. Casson, Eun-Ah Bae, Sarah B. Hesse, Carla Guarino, Rohan Diwanji, Tiquella Hatten, Adam Hinthorne, Jian Huang, Ajeeth K. Pingili, Judy Qiuju Shi, Natasha Iartchouk, Brandon Wilkinson, Jessica Riceberg, Anikó Palfi, Natalie Roy D’Amore, Torsten Hechler, Adnan O. Abu-Yousif
• 5605 · PDF Advanced dual payload antibody-drug conjugates for targeted chemoimmunotherapy X. Margaret Liu, Zhuoxin “Zora” Zhou

在完整检索应用中浏览本分会场 →